Changchun GeneScience Pharmaceutical Co., Ltd.
108
22
28
29
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
1.9%
2 terminated/withdrawn out of 108 trials
93.5%
+7.0% vs industry average
30%
32 trials in Phase 3/4
0%
0 of 29 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (108)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants
Role: lead
Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.
Role: lead
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Role: lead
A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
Role: lead
A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants
Role: lead
To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .
Role: lead
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
Role: lead
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
Role: lead
GS1-144 in Participants With Hepatic Impairment and Healthy Female
Role: lead
A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults
Role: lead
A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)
Role: lead
A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)
Role: lead
Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
Role: lead
A Study of GensSci098 in Subjects With Graves' Disease
Role: lead
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics
Role: lead
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
Role: lead
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Role: lead
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Role: lead
GenSci143 in Participants With Advanced Solid Tumors
Role: lead
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Role: lead